Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients-Reference-Cited by-同舟云学术

Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Published:2022-08-06 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Maechler Melanie¹,Bacher Ulrike²^ORCID,Daskalakis Michael²,Nilius Henning³,Nagler Michael³^ORCID,Taleghani Behrouz Mansouri²,Jeker Barbara¹,Pabst Thomas¹^ORCID

Affiliation:

1. Department of Medical Oncology Bern University Hospital University of Bern Bern Switzerland

2. Department of Hematology and Central Hematology Laboratory Bern University Hospital University of Bern Bern Switzerland

3. University Institute of Clinical Chemistry Inselspital Bern University Hospital University of Bern Bern Switzerland

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3055

Reference14 articles.

1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

2. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

3. Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy

4. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma;Current Issues in Molecular Biology;2024-07-29

2. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?;Transfusion and Apheresis Science;2023-12

3. Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study;Cytotherapy;2023-07

4. Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma;Cancers;2023-01-09